The Hidden Power of Diabetes Drugs in Preserving Kidney Function
Type 2 diabetes is a prevalent metabolic disorder often associated with the progression of diabetic kidney disease (DKD), a leading ...
{"id":15687,"date":"2024-07-29T15:49:30","date_gmt":"2024-07-29T15:49:30","guid":{"rendered":"https:\/\/scienmag.com\/projected-changes-in-statin-and-antihypertensive-therapy-eligibility-with-the-aha-prevent-cardiovascular-risk-equations\/"},"modified":"2024-07-29T15:49:30","modified_gmt":"2024-07-29T15:49:30","slug":"projected-changes-in-statin-and-antihypertensive-therapy-eligibility-with-the-aha-prevent-cardiovascular-risk-equations","status":"publish","type":"post","link":"https:\/\/scienmag.com\/projected-changes-in-statin-and-antihypertensive-therapy-eligibility-with-the-aha-prevent-cardiovascular-risk-equations\/","title":{"rendered":"Projected changes in statin and antihypertensive therapy eligibility with the AHA PREVENT cardiovascular risk equations"},"content":{"rendered":"
About The Study:\u00a0<\/strong>By assigning lower atherosclerotic cardiovascular disease risk predictions, application of the Predicting Risk of cardiovascular disease EVENTs (PREVENT) equations to existing treatment thresholds could reduce eligibility for statin and antihypertensive therapy among 15.8 million U.S. adults.\u00a0<\/strong><\/p>\n <\/p>\n About The Study:\u00a0<\/strong>By assigning lower atherosclerotic cardiovascular disease risk predictions, application of the Predicting Risk of cardiovascular disease EVENTs (PREVENT) equations to existing treatment thresholds could reduce eligibility for statin and antihypertensive therapy among 15.8 million U.S. adults.\u00a0<\/strong><\/p>\n Corresponding Author:<\/strong>\u00a0To contact the corresponding author, Arjun K. Manrai, Ph.D., email\u00a0Arjun_Manrai@hms.harvard.edu.<\/p>\n To access the embargoed study: <\/strong>Visit our For The Media website at this link <\/a><\/p>\n (doi:10.1001\/jama.2024.12537)<\/p>\n Editor\u2019s Note:<\/u>\u00a0Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.<\/p>\n #\u00a0 #\u00a0 #<\/p>\n